Clinical Evaluation of Potential Indicators of Efficacy and Toxicity of Anticancer Therapies

Dear Colleagues,

Recent reports related to cancer biology and the development of cancer treatment modalities, including neoadjuvant therapies (targeted therapies based on specific antibodies or immunotherapies), together with their accompanying clinical challenges, point to the need for continued research in this area. As mentioned in the title, potential indicators may include, but are not limited to, characteristic clinical features that are phenotypically associated with cancer, genetic disorders, markers identified using molecular methods, or other analytes determined in patients’ tissues and body fluids. The study of new parameters in the context of evaluating the effectiveness of oncological treatment during therapy is closely related to its toxicity. The early identification of patients who are likely to benefit from treatment with a reduced risk of adverse effects from its use is one of the priorities in modern oncology. This Special Issue will publish original research and review articles related to the evaluation of various indicators that may be useful in the diagnostic and therapeutic processes of malignancies in the future.

We invite you to publish your papers as part of the Special Issue in the journal Cancers. The topics of this issue are related to the search for new parameters with potential clinical value in diagnostic and therapeutic processes for patients with malignant tumors.

With the development of preclinical studies, a clinical evaluation of the identified indicators is needed. Studies based on materials from patients with malignant tumors provide important information about the possibility of assessing the effectiveness and toxicity of modern therapies. The obtained results, once validated, can be used in oncology in sufficiently large groups of patients. Introducing new parameters into clinical practice will increase time and comfort in the lives of patients with malignant tumors.

This Special Issue aims to publish both experimental and theoretical studies that identify potential indicators that are useful for evaluating the efficacy and toxicity of modern anticancer therapies in clinical specimens from patients with malignancies in various locations. Such topics are consistent with the profile of Cancers, especially in the area of clinical oncology.

Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

1. New predictive factors in patients with malignant cancer treated with neoadjuvant therapy;
2. New predictive markers to monitor the efficacy of immunotherapy in patients with malignancies in various locations;
3. The identification of markers associated with the toxicity of anticancer therapies in patients with malignant tumors (neuro-, cardio-, and nephrotoxicity).

We look forward to receiving your contributions.

Prof. Dr. Beata Kotowicz
Prof. Dr. Anita Chudecka-Glaz
Dr. Anna Dańska-Bidzińska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer
• biomarker
• molecular biomarkers
• immunotherapy
• neoadjuvant chemotherapy
• targeted therapy
• predictive factor
• prognostic factor
• therapy toxicity
• treatment response biomarkers